National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Unusual Cancers of Childhood Treatment (PDQ®)     
Last Modified: 09/05/2008
Health Professional Version
Changes to This Summary (09/05/2008)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Purpose of This PDQ Summary 1

Added text 2 to state that some reference citations in the summary are accompanied by a level-of-evidence designation that is intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches.

Head and Neck Cancers 3

Added text 4 to state that the PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy; added a link to the PDQ summary on Levels of Evidence.

Added text 5 to state that a chemotherapy regimen of carboplatin, epirubicin, vincristine, etoposide, ifosfamide, and dactinomycin has been used in the treatment of metastatic sialoblastoma and has produced a response in one child (cited Scott et al. as reference 71 and added level of evidence: 3iiiDiv).

Thoracic Cancers 6

Added text 7 to state that the PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy; added a link to the PDQ summary on Levels of Evidence.

Added Coulter et al. as reference 47 8.

Abdominal Cancers 9

Added text 10 to state that the PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy; added a link to the PDQ summary on Levels of Evidence.

Added text 11 to state that postoperative treatment with cisplatin, doxorubicin, ifosfamide, and etoposide has produced responses in patients with pancreatoblastoma (cited Lee et al. as reference 41 and added level of evidence: 3iiiA).

Added Hill et al. as reference 51 12 and level of evidence: 3iiiA.

Other Rare Childhood Cancers 13

Added protocol 14 NCI-07-C-0189 as a treatment option under clinical evaluation (cited Herbst et al. and Vidal et al. as references 22 and 23, respectively).



Table of Links

1http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/392.cdr#Section_392
2http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/397.cdr#Section_397
3http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/106.cdr#Section_106
4http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/435.cdr#Section_435
5http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/23.cdr#Section_23
6http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/112.cdr#Section_112
7http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/436.cdr#Section_436
8http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/40.cdr#Section_40
9http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/113.cdr#Section_113
10http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/438.cdr#Section_438
11http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/64.cdr#Section_64
12http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/68.cdr#Section_68
13http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/115.cdr#Section_115
14http://cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/HealthPr
ofessional/433.cdr#Section_433